AMBIT
Acumen at work

Asset Management

MONTHLY NEWSLETTER July 2025

A SECTOR REBORN:
THE RISE OF INDIAN CHEMICAL LEADERSHIP



India's chemical sector has been under pressure to maintain margins over FY24-25, driven by a global slowdown and pricing pressure amid rising fixed costs and volatility in raw material prices. Post the golden era of FY20-22, street extrapolated optimism to FY22-25 with 23% earning CAGR and median EBITDA margin of 25%; however this never came through as revenue CAGR decelerated to -3% and median EBITDA margin crashed to 13% in FY24 but improved to 18% due to business stabilization in H2FY25. Fast forward to FY26 on the back of dismal FY22-25, the street is expecting only a modest recovery of 18% revenue CAGR over FY25-27 with an average EBITDA margin of 18% in FY27 vs 16% in FY25. We believe there is significant scope of upgrades to these assumptions given global channel inventory is at 5-year low, which suggests restocking led demand; recent pricing up-move indicates strong improvement in margins as well, and resultantly, we believe there is scope for upgrades.

FY24-25 has been a tough year for India's chemical sector

FY24-25 period saw significant deceleration in both revenue and EBITDA CAGR across several sub-sector of chemicals when compared to the golden period of FY21-23; during FY23-25 the revenue CAGR was just 1% in commodity chemicals/ -12% in specialty chemicals and 3% in agrochemicals segment while EBITDA CAGR was 2%/-5% and -6% in respective sub-segments. EBITDA margin contraction was ~500bps across 3 sub-segments to an average of 14% vs 19% in FY23. The sector did exceptionally well during the golden era of FY21-23 as revenue CAGR was 27% in commodity chemicals, 57% in specialty chemicals and 24% in the agro segment. The worst sub-sectors during FY23-25 were Amines, which reported revenue/EBITDA CAGR of -14%/-26% vs the golden era CAGR of 26% /9%, Alkali chemicals -10%/-32% revenue and EBITDA CAGR over FY23-25 vs 36%/64% CAGR over FY21-23 and oleo chemicals 39%/47% vs -7%/-16% CAGR.

Exhibit 1: Revenue growth in bull and bear run over FY21-25 across sectors



Source: Company, Bloomberg, Ambit Asset Management

Exhibit 2: EBITDA growth in bull and bear run over FY21-25 across sectors



Source: Company, Bloomberg, Ambit Asset Management

Exhibit 3: Profit growth in bull and bear run over FY21-25 across sectors



Source: Company, Bloomberg, Ambit Asset Management

Exhibit 4: EBITDA margin in bull and bear run over FY21-25 across sectors



Source: Company, Bloomberg, Ambit Asset Management

Exhibit 5: Valuation also saw significant de-rating with P/E and EV/EBITDA multiples correcting by ~13% to ~10% across sub-sectors, majorly in spechem.



Source: Company, Bloomberg, Ambit Asset Management

Exhibit 6: FII ownership declined during this period (~35 companies)



Source: Bloomberg, Ambit Asset Management

Why FY20-22 was a golden period for Indian chemical companies?

Covid period allowed the chemical companies to make record margins led by supply chain constraints from China which led to significant jump in pricing and resultant margins. Globally chemical companies started stocking excess inventories to ensure there is no production disruption given China which is the largest exporter of chemicals was seeing supply chain constraints.

Exhibit 7: Covid and De-stocking saw global inventory rising to record levels as manufacturers' inventories to shipment ratio peaked in 2020



Source: U.S. Census Bureau via FRED, Ambit Asset Management

Exhibit 8: Freight rates peaked led by supply chain disruptions



Source: Bloomberg, Ambit Asset Management

Street got exited on the back of chemical companies reporting good results and this led to several upgrades to the sector. Street started extrapolating the record margins to FY22-25 period as well and resultantly the sector saw ~73% buys and outperformer ratings; coverage for chemical companies also started rising significantly.

Exhibit 9: EBITDA margin improved ~200-500bps over FY19-23 across sectors



Source: Bloomberg, Ambit Asset Management

Exhibit 10: ...as street started extrapolating record margins of FY22 to FY22-25 period



Source: Bloomberg, Ambit Asset Management

Exhibit 11: ....resultantly the sector saw ~73% buys and outperformer ratings



Source: Bloomberg, Ambit Asset Management

Post FY22 the downfall started

With channel inventory at historic high levels in FY22 and easing supply chain disruptions from China the demand exuberance started waning and resultantly the downfall in pricing for Indian chemical companies started. The capex announced during FY21-22 further compounded the sector's woes as rising debt (to fund the capex) strained profitability further.

Exhibit 12: Starting CY23 prices for chemicals started correcting as supply chain disruptions eased out from China














Acrylic Acid Contract China, DEL ($/MT)
3,000
2,500
2,000
1,500
1,000
500
-
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


Acrylonitrile Spot Far East Asia, CFR ($/MT)
3,000
2,500
2,000
1,500
1,000
500
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


Ethyl acetate (CNY/MT)
12,000
10,000
8,000
6,000
4,000
2,000
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


China Phenol Spot Price, FOB (CNY/MT)
12,000
10,000
8,000
6,000
4,000
2,000
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


Propylene Oxide Spot China CNY/MT
20,000
18,000
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


Cyclohexane Spot China CNY/MT
14,000
12,000
10,000
8,000
6,000
4,000
2,000
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


MDI Contract China Domestic Crude, ($/MT)
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25


TDI Contract China, ($/MT)
3,500
3,000
2,500
2,000
1,500
1,000
500
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25













Source: Sector Data, Bloomberg, Ambit Asset Management

Exhibit 13: Actual margin performance was weaker than analyst expansions for FY23-35



Source: Bloomberg, Ambit Asset Management

Exhibit 14: Rising balance sheet debt on the back of chemical companies announcing capex post record profits in FY22 further impacted profitability



Source: Bloomberg, Ambit Asset Management

Why we remain bullish on the sector for FY25-27?

There are three main reasons why we are bullish on the sector: (a) global inventory is at par to decadal levels; (b) finished goods prices have started bottoming out across several products and (c) capex cycle is behind us implying strong FCF generation if revenue growth starts improving.

Exhibit 15: Inventory to shipment ratio declining which would result in volume growth



Source: U.S. Census Bureau via FRED, Ambit Asset Management

Exhibit 16: Chemicals output across the market is expected to grow after being weak over 2022-24, largely supported by Asia pacific region



Source: ACC situation & Outlook (Dec'24), Ambit Asset Management

Pricing bottoming out across several products with sector tailwinds: The sector's realization growth indicates higher dependence on crude oil prices as petrochemicals are the primary raw material for the industry. Crude prices were at average ~$99/bbl which supported strong realization growth in 2022 vs declining crude prices at US$82/bbl in 2024 putting realization pressure on the industry. In the recent pricing data, it is clear that realization looks bottomed out and expected to remain at this level or improve from here on. Asia-Pacific region is projected to lead global growth, driven by strong domestic demand, infrastructure investments, and government support. Countries like India are experiencing significant expansion in chemical production due to a growing industrial base, robust manufacturing capabilities, and increased consumer demand. (Refer exhibit 12)

FCF to see significant growth over FY25-27 despite some pick-up in capex over FY26-28 on import substitution, CDMO and export opportunities: Companies have consistently added new product capabilities to maintain their growth aspirations. The capex of Rs89bn in FY21 over 36 companies rose to Rs133bn in FY22 and Rs167bn in FY23. The capex intensity subsequently declined to Rs142bn in FY24 and Rs148bn in FY25 due to uncertain demand and pricing environment. We expect capex to revive again from FY26 with focus on rising export and import substitution opportunities. The new products are forward-integrated into the existing product portfolio, such as fluoropolymers for SRF, phenol/acetone downstream for Deepak Nitrite, chloro-toluene value chain for Aarti Industries antioxidants for Vinati, etc. Companies like PI and SRF are also building on their capabilities to venture into new categories like pharma CRDMO, API and intermediates. We expect these companies to continue to build on their capabilities given: a) customer relations, b) global footprint, and c) operational track record supported by sound balance sheets. They will continue to leverage their learning of the last two decades and increase their wallet share in export markets. They will continue to attract new business given their operational delivery and process capabilities supported by R&D.

Exhibit 17: Capex cycle to continue to bake growing opportunities rising in import substitution, CDMO and exports



Source: Bloomberg, Ambit Asset Management

Despite, some surge in capex, we model significant growth in FCF as seen in the chart below led by strong earnings growth and improvement in working capital cycle. We have seen that industry was generating ~Rs104bn FCF in FY21 which declined to Rs27bn/76bn/31bn over FY22-24. As the company's performance expected to improve on the back of demand, pricing and margin betterment coupled with operating efficiencies, FCF is expected to increase to Rs83bn/74bn and 108bn over FY25-27, despite ongoing capex across import substitution, CDMO and export opportunities.

Exhibit 18: FCF to remain healthy despite ongoing capex cycle



Source: Bloomberg, Ambit Asset Management

Foreign Institutional Investors (FIIs) have been quietly increasing exposure to the chemical sector since the last 9 months given their knowledge of the global chemical cycle. Similar behavior we saw from them in 2022 to 2024 when they did this in Auto and Capital Goods sectors from 2022 to 2024 giving them handsome rewards.

Valuation has become favourable as sector trades at discount to long term average: Valuations across chemical companies are now at discount compared to 5 year averages and FCF yields are promising. We believe this gives a lot of margin of safety for investors to make money if they are patient enough to ride the cycle.

Exhibit 19: Valuation looks reasonable considering industry tailwinds



Source: Bloomberg, Ambit Asset Management

Exhibit 20: DIIs shareholding (%) in chemical sectors has been going up now for 6 quarters (Top 15 companies seeing this trend)

Company Name	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Change in last 6 qtrs(bps)
Sudarshan Chemicals	13.6	17.5	20.9	19.8	18.6	23.6	999
Jubilant Ingrevia	11.2	13.6	14.1	15.5	16.0	15.9	473
PI Industries	23.2	24.3	26.0	26.4	27.2	27.6	442
Deepak Nitrite	18.9	19.3	21.2	22.3	23.2	23.2	429
Aarti Industries	15.8	17.3	18.6	18.1	17.9	20.0	412
SRF Ltd	14.5	16.0	16.6	17.8	17.8	18.5	395
PCBL Chemicals	7.5	6.9	7.7	8.0	7.9	10.2	268
Nocil	2.8	3.5	4.4	6.1	5.9	5.3	243
Gujatat Fluorochemicals	8.6	8.8	9.6	9.6	10.0	10.7	211
Sumitomo Chemicals	6.0	6.6	7.1	7.0	7.0	8.1	211
Galaxy Surfactants	2.2	3.1	3.5	3.8	4.1	4.2	200
Vinati Organics	7.6	7.3	6.7	7.3	7.6	9.2	165
UPL Ltd	16.8	15.3	15.7	17.6	18.7	18.4	154
Tata Chemicals	20.5	20.0	19.9	20.4	21.7	22.0	152
GHCL Ltd	8.6	8.3	9.3	9.8	10.4	10.1	151

Source: Bloomberg, Ambit Asset Management

Exhibit 21: FIIs shareholding (%) in chemical sectors has been going up now for 6 quarters (Top 15 companies seeing this trend)

Company Name	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Change in last 6 qtrs(bps)
Navin Fluorine	15.9	15.6	18.0	18.2	18.6	20.2	424
Sudarshan Chemicals	4.2	4.5	6.7	8.4	8.7	8.0	374
Neogen Chemicals	4.5	4.6	4.7	8.2	7.7	7.8	328
Sharda Cropchem	2.1	2.1	2.0	2.5	3.8	4.7	263
Rallis India	9.2	9.2	9.5	10.6	11.9	11.4	220
Laxmi Organics	0.7	0.9	1.1	1.7	2.0	2.5	181
Atul Ltd	8.1	8.5	8.6	9.7	11.2	9.8	173
GHCL Chemicals	24.7	25.0	24.8	25.7	25.4	26.1	140
Aether Industries	2.0	2.2	2.9	3.2	3.3	3.3	136
Nocil Ltd	7.0	7.8	7.8	7.9	7.8	8.2	117
Fine Organics	3.6	4.5	4.9	4.9	5.2	4.7	108
Sumitomo Chemicals	2.6	2.7	3.1	3.5	3.6	3.6	102
Dhanuka Agritech	1.3	1.5	1.5	2.0	2.2	2.2	85
Jubilant Ingrevia	6.4	6.6	6.6	7.2	6.9	7.1	77
Balaji Amines	4.6	4.9	5.1	5.3	5.2	5.1	51

Source: Bloomberg, Ambit Asset Management

Exhibit 22: Similar behavior we saw from FIIs in auto and capital goods sector in 2022 to 2024 which gave them handsome rewards (% of inflows and outflow)



Source: Bloomberg, Ambit Asset Management

Exhibit 23: FCF yield on FY27 looks promising ...



Source: Bloomberg, Ambit Asset Management

We are bullish on chemicals across all our portfolio strategies and few of our portfolio picks are as given below:

Alkyl Amines

We anticipate Alkyl's performance to strengthen from FY26 onward, supported by a:

- Positive outlook for its core end-user industries—pharmaceuticals and agrochemicals.
- Ministry of Finance has approved an anti-dumping duty of ~12–28% on acetonitrile imports from China, Russia, and Taiwan, which collectively account for a~90% of such imports which expected to alleviate pricing pressure starting FY26.
- Alkyl is also undertaking a capex of Rs1bn towards a specialty product, further reinforcing its growth trajectory.
- The company boasts a diversified product portfolio, disciplined capital allocation, and a robust balance sheet, all under the leadership of a technocrat promoter.

Neogen Chemicals

Neogen Chemicals is one of India's leading manufacturers of Bromine –based and Lithium based specialty chemicals. The recent fire accident at Neogen's Dahej SEZ plant coupled with timelines for ramping up the battery chemical business continue to be pushed out led by delays in commissioning of Lithium ion battery plants which hurt performance in recent times However, long term performance looks promising considering.

- Neogen is the best play in the battery chemical space considering available capacities with Japanese proven technology.
- Revival in agrochemical cycle.
- Rising opportunities in CDMO side which going to support growth in base business.

PI Industries

Despite headwinds in the agrochemical industry during FY23–25, PI Industries delivered a strong performance, achieving a CAGR of 19% in revenue, 21% in EBITDA, and 21% in PAT with EBITDA margin of expanding by ~350bps to 27% in FY25. Looking ahead, we expect PI Industries to:

- Maintain its growth momentum, supported by global recovery in agrochemical demand.
- Robust cash reserve of ~Rs40bn, enabling potential inorganic growth opportunities.
- Continued scaling of its Pharma segment, driving further margin improvement and commercialization of its novel agrochemical molecule.
- Pioxaniliprole—a next-generation diamide insecticide. Notably, PI is the only Indian chemical company currently developing an agchem New Chemical Entity (NCE). Pioxaniliprole is in Phase III trials and is anticipated to be commercialized in the future, reinforcing the company's leadership in innovation.

Insecticides India

Well positioned to capitalise on the thriving agrochemical sector:

- Company is focusing on its high margin Maharatna and Focus Maharatna products, which will drive profitability improvement.
- Senior hires undertaken of several GM level employees; discussions are ongoing with CXO level employees with strong incentive packages which will provide human capital boost.
- Production from Gujarat facility will commence in June 2025 - with a sales potential for INR 350-400cr over 3 years. The capex in Rajasthan, which will be completed by June 2026, has a similar revenue potential.

Exhibit 24: Price performance/charts

Source: BSE, Ambit Asset Management

Summary

- Post-COVID Overconfidence: FY20–22 boom led to overcapacity and unrealistic growth expectations in the chemical sector.
- Reality Check: Peaking inventories, falling realizations, and high fixed costs triggered a prolonged downcycle.
- Capex Strain: Aggressive investments during the upcycle became burdensome as demand softened, impacting profitability and leverage.
- Stabilization Phase: Inventory levels are now leaner, and pricing pressures have largely bottomed out, creating a more balanced environment.
- Shift to Value Creation: Companies are moving from expansion to execution—focusing on complex, higher-margin segments like pharma intermediates, agro-specialties, CDMO, and advanced materials.
- India's Advantage: Regional momentum, policy support, and global supply chain diversification are boosting India's role in the chemical value chain.
- Outlook Turning Positive: With cash flows recovering, margins poised to expand, and balance sheets repairing, the sector is set for a potential rerating.
- Cycle Reset Completed: What seemed like a deep trough may mark the beginning of a more resilient and strategically sound growth phase.
- We believe Indian chemicals and particularly sub-segments like agrochemicals, contract manufacturing, import substitution, and supply diversification are poised for a structural recovery, and our portfolios are well placed to take advantage of the same.

AMBIT
Acumen at work
Asset Management

INVEST SUCCESSFULLY ACROSS MARKET CYCLES WITH AMBIT ASSET MANAGEMENT



- Successful investing takes acumen
- The acumen to have a solution for every need
- The acumen to navigate volatile conditions
- The acumen to always stay true to character
- At Ambit Asset Management, it is this acumen that helps you invest successfully, with products that stay true to character across market cycles

To know more visit : https://www.ambit.co/asset-management

AMBIT
Acumen at work
Asset Management

4000 Cr+ Aum. 'True To Character' Products



Our Presence


MUMBAI


NEW DELHI


BENGALURU


HYDERABAD


CHANDIGARH


JAIPUR


BHOPAL


GIFT CITY


CHENNAI


KOLKATA


KOLHAPUR

Our Team

SUSHANT BHANSALI
CEO

Sushant has over 24 years of experience. Before Asset Management, he led Ambit's Principal Investment business, where he cut his teeth investing in listed equities from Ambit's Balance Sheet. Sushant is a Chartered Accountant, holds a Post-Graduate Diploma in Business Management from Indian School of Business (ISB), and has also completed the Advanced Management Program (AMP) at Harvard Business School (HBS).

DHIRAJ AGARWAL
MANAGING DIRECTOR - AMBIT INVESTMENT MANAGERS

Dhiraj Agarwal, Managing Director of Ambit Investment Managers, has 30+ years of financial market experience. He co-headed Institutional Equities at Ambit Capital, led sales at Standard Chartered India, worked with Boyer Allan Investment Management (a UK based Hedge Fund), and co-founded Sharekhan. He holds an MBA from IIM Bangalore and is an SRCC graduate.

SIDDHARTHA RASTOGI
COO & HEAD OF SALES

Siddhartha Rastogi is the Chief Operating Officer and Head of Sales at Ambit Asset Management, with over 23 years of experience in financial markets. A key pillar of the Ambit Group for more than 15 years, he was also a co-founder of IIFL Wealth. Previously, he led HSBC's Peddar Road branch — the largest and most profitable wealth branch in the country — as its youngest Branch Head. He is a Commerce Honours graduate from the University of Delhi, a Company Secretary (Intermediate), and holds a PGDBA from NMIMS, Mumbai.

SHALINI GUPTA
DIRECTOR - FAMILY OFFICES & INSTITUTIONS

Shalini Gupta brings over two and a half decades of distinguished expertise in asset management, capital markets, and investment strategy. As Director, Family Office , she spearheads institutional investors and family offices engagements focusing on scalable bespoke investment solutions. Her career spans key roles majorly at Alchemy Capital and Principal PNB Asset Management, where she spearheaded Markets as well as established and built institutional partnerships. Shalini holds an MBA & Bcom from University of Pune , enabling her to blend financial expertise with strategic vision.

DIPTI MEHTA
DIRECTOR - OFFSHORE SALES

Dipti has 19+ years of experience, transitioning from a successful sell-side career in institutional equity sales, covering FII clients across the Western Hemisphere. She has worked with firms like Ambit Capital, B&K Securities, and Haitong Securities. Dipti holds a Post-Graduate degree in Finance from NLDSMR.

TRILOK AGARWAL
FUND MANAGER - EQUITY

Trilok has over 18 years of experience in equities and asset management. Prior to Ambit, he worked with Dymon Asia Capital and Aditya Birla Sun Life Limited, where he was managing funds over INR 40 billion. Due to his superlative performance, he won several accolades and nominated as a Young Leader. Trilok has completed his post graduation in Finance from MET and BMS – Dual specialization from University of Mumbai.

BHARGAV BUDDHADEV
FUND MANAGER - EQUITY

Bhargav, with 20+ years of experience in equities and asset management, has worked at Kotak Mutual Fund and Ambit Institutional Equities. He pioneered the Beachcombing Series at Ambit Institutional Equities, a small-cap product that earned his team a top-three ranking in Asia Money polls. Bhargav is a Chartered Accountant and holds an MBA in Finance.

SIDDHARTH BOTHRA
FUND MANAGER - EQUITY

Siddharth, an investment professional with 25+ years of experience, has managed prominent funds like MOFSL Focused Large Cap 25 and Aggressive Hybrid, overseeing INR 150 billion in assets at its peak. Known for his expertise across large-cap, mid-cap, flexi-cap, and hybrid funds, he consistently ranked Focused 25 among the top 10 in its category for 9 of 11 years. Siddharth holds an MBA from ISB, Hyderabad, with an International MBA Exchange at NYU Stern School of Business, New York.

Our Journey


1997
Ambit RSM is born as a boutique investment bank
2004
Moves to its home, Ambit House, a landmark building in Lower Parel
2006
Launches the Institutional Equities business
2009
Ambit Finvest, the non-banking financial services arm, is set up
2009
Launches the Private Wealth business
2012
The Equity Capital Markets practice is launched
2015
Ambit launches its PMS offering: Ambit Good & Clean
2017
Ambit launches its PMS offering: Ambit Coffee Can & Ambit Emerging Giants
2018
Ambit Finvest forays into SME Lending via an inorganic growth route
2019
Ambit strengthens its wealth management business, launches the Global Private Client platform
2020
Ambit Finvest raises equity capital from Adar Poonawalla
2021
Ambit launches its PMS offering: Ambit TenX
2023
In partnership with Daiwa
2023
Ambit launches its AIF offering: Ambit 365
2023
Signs Chess GM Vidit Gujrathi as Brand Ambassador
2024
Ambit launches its PMS offering: Ambit Micro Marvels
2024
Ambit Finvest partners with Daiwa through a minority stake
2025
Ambit Asset Management launches Ambit India Ascension Fund in partnership with Daiwa Asset Management.
Milestone – over INR 40 billion AUM

Ambit Coffee Can Portfolio

At Coffee Can Portfolio, we do not attempt to time commodity/investment cycles or political outcomes and prefer resilient franchises in the retail and consumption-oriented sectors. The Coffee Can philosophy has an unwavering commitment to companies that have consistently sustained their competitive advantages in core businesses despite being faced with disruptions at regular intervals. As the industry evolves or is faced with disruptions, these competitive advantages enable such companies to grow their market shares and deliver long-term earnings growth.

Exhibit 25:

Ambit Coffee Can Portfolio point-to-point performance



Source: Ambit Coffee Can Portfolio inception date is June 20, 2017;
**1M Return: 1st - 30th Jun'25; 3M Return: 1st Apr'25 – 30th Jun'25; 6M Return: 1st Jan'25 – 30th Jun'25; 1Y Return: 1st Jul'24 – 30th Jun'25
*Nifty 50 TRI is the selected benchmark for the Ambit Coffee Can Portfolio. The performance related information provided herein is not verified by SEBI.

Exhibit 26:

Ambit Coffee Can Portfolio calendar year performance



Source: Ambit Coffee Can Portfolio inception date is June 20, 2017;
*Nifty 50 TRI is the selected benchmark for the Ambit Coffee Can Portfolio. The performance related information provided herein is not verified by SEBI.

Ambit Good & Clean Midcap Portfolio

Ambit's Good & Clean strategy provides long-only equity exposure to Indian businesses that have an impeccable track record of clean accounting, good governance, and efficient capital allocation. Ambit's proprietary 'forensic accounting' framework helps weed out firms with poor quality accounts, while our proprietary 'greatness' framework helps identify efficient capital allocators with a holistic approach for consistent growth. Our focus has been to deliver superior risk-adjusted returns with as much focus on lower portfolio drawdown as on return generation. Some salient features of the Good & Clean strategy are as follows:

1. Process-oriented approach to investing: Typically starting at the largest 500 Indian companies, Ambit's proprietary frameworks for assessing accounting quality and efficacy of capital allocation help narrow down the investible universe to a much smaller subset. This shorter universe is then evaluated on bottom-up fundamentals to create a concentrated portfolio of no more than 20 companies at any time.
2. Long-term horizon and low churn: Our holding horizons for investee companies are 3-5 years and even longer with annual churn not exceeding 20-25% in a year. The long-term orientation essentially means investing in companies that have the potential to sustainably compound earnings, with these compounding earnings acting as the primary driver of investment returns over long periods.
3. Low drawdowns: The focus on clean accounting and governance, prudent capital allocation, and structural earnings compounding allow participation in long-term return generation while also ensuring low drawdowns in periods of equity market declines.

Exhibit 27:

Ambit Good & Clean Midcap Portfolio point-to-point performance



Source: Ambit Good & Clean Mid cap Portfolio inception date is Mar 12, 2015;
**1M Return: 1st - 30th Jun'25; 3M Return: 1st Apr'25 – 30th Jun'25; 6M Return: 1st Jan'25 – 30th Jun'25; 1Y Return: 1st Jul'24 – 30th Jun'25
*BSE 500 TRI is the selected benchmark for the Ambit Good & Clean Mid cap. The performance related information provided herein is not verified by SEBI.

Exhibit 28:

Ambit Good & Clean Midcap Portfolio calendar year performance



Source:Ambit Good & Clean Mid cap Portfolio inception date is Mar 12, 2015;
*BSE 500 TRI is the selected benchmark for the Ambit Good & Clean Mid cap. The performance related information provided herein is not verified by SEBI.

Ambit Emerging Giants Small Cap Portfolio

Small caps with secular growth, superior return ratios and no leverage – Ambit's Emerging Giants Small Cap portfolio aims to invest in small-cap companies with market-dominating franchises and a track record of clean accounting, governance and capital allocation. The fund typically invests in companies with market caps less than INR 10,000cr. These companies have excellent financial track records, superior underlying fundamentals (high RoCE, low debt), and the ability to deliver healthy earnings growth over long periods of time. However, given their smaller sizes, these companies are not well discovered, owing to lower institutional holdings and lower analyst coverage. Rigorous framework-based screening coupled with extensive bottom-up due diligence led us to a concentrated portfolio of 18-20 emerging giants.

Exhibit 29:

Ambit Emerging Giants Small Cap Portfolio point-to-point performance

Source: Ambit Emerging Giants Small cap Portfolio inception date is Dec 1, 2017;
**1M Return: 1st - 30th Jun'25; 3M Return: 1st Apr'25 – 30th Jun'25; 6M Return: 1st Jan'25 – 30th Jun'25; 1Y Return: 1st Jul'24 – 30th Jun'25
*BSE 500 TRI is the selected benchmark for the Ambit Emerging Giants Small cap. The performance related information provided herein is not verified by SEBI.

Exhibit 30:

Ambit Emerging Giants Small Cap Portfolio calendar year performance



Source: Ambit Emerging Giants Small cap Portfolio inception date is Dec 1, 2017;
*BSE 500 TRI is the selected benchmark for the Ambit Emerging Giants Small cap. The performance related information provided herein is not verified by SEBI.

Ambit TenX Portfolio

Ambit TenX Portfolio gives investors an opportunity to participate in the India growth story as the Indian GDP heads towards a US$10tn mark over the next 12-15 years. Mid and Small corporates are expected to be the key beneficiaries of this growth. The portfolio intends to capitalize on this opportunity by identifying and investing in primarily mid & small cap companies that can grow their earnings 10x over the same period implying 18-21% CAGR. Key features of this portfolio would be as follows: Key features of this portfolio would be as follows:

1. Longer-term approach with a concentrated portfolio: Ideal investment duration of >5 year with 15-20 stocks.
2. Key driving factors: Low penetration, strong leadership, light balance sheet.
3. Forward-looking approach: Relying less on historical performance and more on future potential while not deviating away from the Good & Clean philosophy.

Exhibit 31:

Ambit TenX Portfolio point-to-point performance



Source: Ambit TenX Portfolio inception date is Dec 13, 2021;
**1M Return: 1st - 30th Jun'25; 3M Return: 1st Apr'25 – 30th Jun'25; 6M Return: 1st Jan'25 – 30th Jun'25; 1Y Return: 1st Jul'24 – 30th Jun'25
*BSE 500 TRI is the selected benchmark for the Ambit TenX Portfolio. The performance related information provided herein is not verified by SEBI.

Exhibit 32:

Ambit TenX Portfolio calendar year performance



Source: Ambit TenX Portfolio inception date is Dec 13, 2021;
*BSE 500 TRI is the selected benchmark for the Ambit TenX Portfolio. The performance related information provided herein is not verified by SEBI.

Ambit Micro Marvels Portfolio

We aim to create a portfolio that invests predominantly in micro-cap companies with the potential of delivering superior earnings growth and generating relatively better risk-adjusted performance over a long period of time.

Ambit's proprietary 'forensic accounting' framework helps weed out firms with poor quality accounts while our proprietary 'greatness' framework helps identify efficient capital allocators. The result is a concentrated portfolio of 20-25 stocks that draws down less than the market in corrections and has low churn.

Key Features of Portfolio Companies:

1. High earnings growth companies with low leverage,
2. Market leaders or challengers with strong moat around brand, distribution, technology, and innovation,
3. Strong corporate governance coupled with apt capital allocation.

Exhibit 33:

Ambit Micro Marvels Portfolio point-to-point performance



Source: Ambit Micro Marvels Portfolio inception date is Jul 29, 2024;
**1M Return: 1st - 30th Jun'25; 3M Return: 1st Apr'25 – 30th Jun'25; 6M Return: 1st Jan'25 – 30th Jun'25; 1Y Return: 1st Jul'24 – 30th Jun'25
*BSE 500 TRI is the selected benchmark for the Ambit Micro Marvels Portfolio. The performance related information provided herein is not verified by SEBI.

Exhibit 34:

Ambit Micro Marvels Portfolio calendar year performance



Source: Ambit Micro Marvels Portfolio inception date is Jul 29, 2024;
*BSE 500 TRI is the selected benchmark for the Ambit Micro Marvels Portfolio. The performance related information provided herein is not verified by SEBI.

AMBIT
Acumen at work
Asset Management

For any queries, please contact:
Phone: +91 22 6623 3281 | Email - amsales@ambit.co
Registered office: Ambit Investment Advisors Private Limited - Ambit House, 449, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013.

Corporate office: Ambit Investment Advisors Private Limited - 2103/2104, 21st Floor, One Lodha Place, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013.

Statutory details:
Ambit Investment Advisors Private Limited ("Ambit"), is a registered Portfolio Manager with Securities and Exchange Board of India vide registration number INP000005059. Ambit is also an Investment Manager to Ambit Investment Advisors Trust – Category III which is registered with SEBI as Alternate Investment Fund under SEBI (Alternative Investment Funds) Regulations, 2012 vide registration no. IN/AIF3/25-26/1833.

Disclaimer & disclosures:
This document is confidential and is intended only for the personal use of the prospective investors / contributors (hereinafter referred as the Clients or you) to whom it is addressed or delivered and must not be reproduced or redistributed in any form to any other person without the prior consent of Ambit.

Returns of individual client may differ depending on the timing of entry and exit, timing of additional flows and redemptions, individual client mandates, specific portfolio construction characteristics or structural parameters which have a bearing on individual portfolio performance. This document is neither approved, certified nor are its contents verified by SEBI. The performance related information provided herein is not verified by SEBI.

Returns are calculated using TWRR method as prescribed under revised SEBI (Portfolio Managers) Regulations, 2020. Performance is net of all fees and expenses. Past performance is not a reliable indicator of future results. Please note that performance of your portfolio may vary from that of other investors and that generated by the Investment Approach across all investors because of 1) the timing of inflows and outflows of funds; and 2) differences in the portfolio composition because of restrictions and other constraints. For comparative Performance relative to other Portfolio Managers within the selected Strategy, please visit: bit.ly/APMI_PMS. Clients are not being offered any guaranteed / assured returns.

This presentation / newsletter / report is strictly for information and illustrative purposes only and should not be considered to be an offer, or solicitation of an offer, to buy or sell any securities or to enter into any Portfolio Management agreements. This presentation / newsletter / report may contain confidential or proprietary information and no part of this presentation / newsletter / report may be reproduced in any form without its prior written consent to Ambit. All opinions, figures, charts/ graphs, estimates and data included in this presentation / newsletter / report is subject to change without notice. Any dissemination, copying or circulation of this communication in any form is strictly prohibited. This material should not be circulated in countries where restrictions exist on soliciting business from potential clients residing in such countries. Recipients of this material should inform themselves about and observe any such restrictions. Recipients shall be solely liable for any liability incurred by them in this regard and will indemnify Ambit for any liability it may incur in this respect.

This presentation / newsletter / report is prepared by Ambit strictly for the specified audience and is not intended for distribution to public and is not to be disseminated or circulated to any other party outside of the intended purpose. If you receive a copy of this presentation / newsletter / report and you are not the intended recipient, you should destroy this immediately.

Neither Ambit nor any of their respective affiliates or representatives make any express or implied representation or warranty as to the adequacy or accuracy of the statistical data or factual statement concerning India or its economy or make any representation as to the accuracy, completeness, reasonableness or sufficiency of any of the information contained in the presentation / newsletter / report herein, or in the case of projections, as to their attainability or the accuracy or completeness of the assumptions from which they are derived, and it is expected each prospective investor will pursue its own independent due diligence. In preparing this presentation / newsletter / report, Ambit has relied upon and assumed, without independent verification, the accuracy and completeness of information available from public sources. Accordingly, neither Ambit nor any of its affiliates, shareholders, directors, employees, agents or advisors shall be liable for any loss or damage (direct or indirect) suffered as a result of reliance upon any statements contained in, or any omission from this presentation / newsletter / report and any such liability is expressly disclaimed.

Ambit does not guarantee the future performance or any level of performance relating to any products of Ambit or any other third-party service provider. Investment in any product including mutual fund or in the product of third-party service provider does not provide any assurance or guarantee that the objectives of the product are specifically achieved. Ambit shall not be liable for any losses that you may suffer on account of any investment or disinvestment decision based on the communication or information or recommendation received from Ambit on any product. Further Ambit shall not be liable for any loss which may have arisen by wrong or misleading instructions given by you whether orally or in writing. The name of the product does not in any manner indicate their prospects or return.

The Investment Approach 'Ambit Coffee Can Portfolio' has been migrated from Ambit Capital Private Limited to Ambit Investments Advisors Private Limited. Hence some of the information in this presentation may belong to the period when this product was managed by Ambit Capital Private Limited.

This document may include certain forward looking words, statements and scenario which contain words or phrases such as "believe", "expect", "anticipate", "estimate", "intend", "plan", "objective", "goal", "project", "endeavor" and similar expressions or variations of such expressions that are forward looking statements, words and scenario. Actual outcomes may differ materially from those suggested by the forward –looking statements due to risks, uncertainties or assumptions.

Risk factors:
You are expected to take into consideration all the risk factors including financial conditions, risk-return profile, tax consequences, etc. You understand that the past performance or name of the portfolio or any similar product do not in any manner indicate surety of performance of such product or portfolio in future. You further understand that all such products are subject to various market risks, settlement risks, economical risks, political risks, business risks, and financial risks etc. and there is no assurance or guarantee that the objectives of any of the strategies of such product or portfolio will be achieved. You are expected to thoroughly go through the terms of the arrangements / agreements and understand in detail the risk-return profile of any security or product of Ambit or any other service provider before making any investment. You should also take professional / legal /tax advice before making any decision of investing or disinvesting. The investment relating to any products of Ambit may not be suited to all categories of investors. Ambit or Ambit associates may have financial or other business interests that may adversely affect the objectivity of the views contained in this presentation / newsletter / report. Prospective investors are advised to review the Disclosure document, client agreement and other related documents carefully in its entirety and consult their legal, tax and financial advisors to determine possible legal, tax and financial or any other consequences of investing under this Portfolio, before making an investment decision.

Asset Management

Ambit Investment Advisors Private Limited - 2103/2104, 21st Floor,
One Lodha Place, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013.
Phone: +91 22 6623 3281 | Email - amsales@ambit.co | www.ambit.co/asset-management